Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Colorcon
Healthtrust
Farmers Insurance
Boehringer Ingelheim
Daiichi Sankyo
McKinsey
Express Scripts
Accenture

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,461,211

« Back to Dashboard

Which drugs does patent 8,461,211 protect, and when does it expire?

Patent 8,461,211 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in thirty-six countries.
Summary for Patent: 8,461,211
Title:Use for budesonide and formoterol
Abstract: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.
Inventor(s): Bauer; Carl-Axel (Lund, SE), Trofast; Jan (Lund, SE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:12/982,360
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 8,461,211

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,461,211

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9703407Sep 19, 1997

Non-Orange Book US Patents Family Members for Patent 8,461,211

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,006,189,587 ➤ Try a Free Trial
7,897,646 Use for budesonide and formoterol ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,461,211

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 013506 ➤ Try a Free Trial
Austria 222106 ➤ Try a Free Trial
Austria 329599 ➤ Try a Free Trial
Australia 757235 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Daiichi Sankyo
Federal Trade Commission
Cantor Fitzgerald
Chinese Patent Office
Chubb
McKesson
AstraZeneca
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.